TR201903209T4 - Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. - Google Patents
Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. Download PDFInfo
- Publication number
- TR201903209T4 TR201903209T4 TR2019/03209T TR201903209T TR201903209T4 TR 201903209 T4 TR201903209 T4 TR 201903209T4 TR 2019/03209 T TR2019/03209 T TR 2019/03209T TR 201903209 T TR201903209 T TR 201903209T TR 201903209 T4 TR201903209 T4 TR 201903209T4
- Authority
- TR
- Turkey
- Prior art keywords
- high density
- lipid
- density lipoprotein
- formulation
- production method
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000015779 HDL Lipoproteins Human genes 0.000 title abstract 2
- 108010010234 HDL Lipoproteins Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 2
- 102000007592 Apolipoproteins Human genes 0.000 abstract 2
- 108010071619 Apolipoproteins Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 abstract 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 239000002516 radical scavenger Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Nispeten daha düşük toksisitesi bulunan yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu, ApoAI veya bunun parçası gibi bir apolipoprotein, bir lipid veya bir insana uygulandığında normalde karaciğer toksisitesine neden olan miktarının yaklaşık %5-50?si olan bir seviyede bir temizleyici içerir. Lipid, yaklaşık 30-50g/L şeklinde optimal olarak fosfatidilkolindir ve apolipoprotein:lipidin molar oranı, optimal olarak 1:40 ila 1:75 aralığındadır. Formülasyon, kardiyovasküler hastalık, akut koroner sendroma (ACS) dahil hiperkolesterolemi ve hipokolesterolemi, ateroskleroz ve miyokard enfarktüsü gibi hastalıkların veya durumların tedavi edilmesine yönelik kullanışlıdır.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35992510P | 2010-06-30 | 2010-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201903209T4 true TR201903209T4 (tr) | 2019-03-21 |
Family
ID=45401226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03209T TR201903209T4 (tr) | 2010-06-30 | 2011-06-30 | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8999920B2 (tr) |
| EP (3) | EP2588113B1 (tr) |
| JP (2) | JP5989641B2 (tr) |
| KR (1) | KR101782309B1 (tr) |
| CN (2) | CN105396122B (tr) |
| AU (1) | AU2011274238B2 (tr) |
| CA (1) | CA2803031C (tr) |
| DK (2) | DK3178481T3 (tr) |
| ES (2) | ES2718234T3 (tr) |
| HU (2) | HUE042391T2 (tr) |
| IL (1) | IL223815A (tr) |
| MX (1) | MX2012014928A (tr) |
| PL (2) | PL3178481T3 (tr) |
| SG (1) | SG186386A1 (tr) |
| TR (1) | TR201903209T4 (tr) |
| TW (1) | TWI531388B (tr) |
| WO (1) | WO2012000048A1 (tr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201903209T4 (tr) | 2010-06-30 | 2019-03-21 | Csl Ltd | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
| SG11201509565VA (en) * | 2013-06-05 | 2015-12-30 | Csl Ltd | Process for preparing apolipoprotein a-i (apo a-i) |
| KR102437202B1 (ko) * | 2013-08-08 | 2022-08-29 | 시에스엘 리미티드 | 오염 제거 방법 |
| EP2853259A1 (en) | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| KR101563403B1 (ko) * | 2013-11-05 | 2015-10-26 | 영남대학교 산학협력단 | 지방물질의 안전성 평가방법 |
| SG11201609084QA (en) | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| WO2016104690A1 (ja) * | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| CA3032229A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
| KR20190084095A (ko) * | 2016-11-10 | 2019-07-15 | 시에스엘 리미티드 | 심근경색의 재구성된 고밀도 지질단백질 치료 |
| US20200261549A1 (en) * | 2017-11-07 | 2020-08-20 | Alphacore Pharma Llc | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms |
| WO2019133358A2 (en) * | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| CN1283313C (zh) | 2001-09-28 | 2006-11-08 | 埃斯佩里安医疗公司 | α螺旋状载脂蛋白或HDL关联蛋白在制备局部给药预防和治疗再狭窄的药物中的用途 |
| US20040067873A1 (en) | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
| US20040038891A1 (en) | 2002-05-17 | 2004-02-26 | Bisgaier Charles L. | Methods and compositions for the treatment of ischemic reperfusion |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| SG183743A1 (en) | 2007-08-17 | 2012-09-27 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2010057203A2 (en) * | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| TR201903209T4 (tr) | 2010-06-30 | 2019-03-21 | Csl Ltd | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. |
| DK2767546T3 (en) | 2011-02-07 | 2019-02-04 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and their preparation and uses |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2011
- 2011-06-30 TR TR2019/03209T patent/TR201903209T4/tr unknown
- 2011-06-30 EP EP11799979.7A patent/EP2588113B1/en active Active
- 2011-06-30 WO PCT/AU2011/000819 patent/WO2012000048A1/en active Application Filing
- 2011-06-30 US US13/805,488 patent/US8999920B2/en active Active
- 2011-06-30 MX MX2012014928A patent/MX2012014928A/es active IP Right Grant
- 2011-06-30 PL PL16203579T patent/PL3178481T3/pl unknown
- 2011-06-30 JP JP2013516907A patent/JP5989641B2/ja active Active
- 2011-06-30 ES ES16203579T patent/ES2718234T3/es active Active
- 2011-06-30 HU HUE16203579A patent/HUE042391T2/hu unknown
- 2011-06-30 EP EP18215066.4A patent/EP3492085A1/en active Pending
- 2011-06-30 DK DK16203579.4T patent/DK3178481T3/en active
- 2011-06-30 EP EP16203579.4A patent/EP3178481B1/en active Active
- 2011-06-30 CN CN201510593566.4A patent/CN105396122B/zh active Active
- 2011-06-30 TW TW100123185A patent/TWI531388B/zh active
- 2011-06-30 KR KR1020137002377A patent/KR101782309B1/ko active IP Right Grant
- 2011-06-30 AU AU2011274238A patent/AU2011274238B2/en active Active
- 2011-06-30 HU HUE11799979A patent/HUE032560T2/en unknown
- 2011-06-30 SG SG2012093076A patent/SG186386A1/en unknown
- 2011-06-30 DK DK11799979.7T patent/DK2588113T3/en active
- 2011-06-30 ES ES11799979.7T patent/ES2617977T3/es active Active
- 2011-06-30 PL PL11799979T patent/PL2588113T3/pl unknown
- 2011-06-30 CA CA2803031A patent/CA2803031C/en active Active
- 2011-06-30 CN CN201180036314.1A patent/CN103118683B/zh active Active
-
2012
- 2012-12-23 IL IL223815A patent/IL223815A/en active IP Right Grant
-
2015
- 2015-02-27 US US14/633,880 patent/US9439946B2/en active Active
-
2016
- 2016-06-02 JP JP2016110551A patent/JP2016188226A/ja active Pending
- 2016-08-19 US US15/241,895 patent/US10335457B2/en active Active
-
2019
- 2019-06-19 US US16/445,937 patent/US11058747B2/en active Active
-
2021
- 2021-07-06 US US17/368,464 patent/US11723953B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903209T4 (tr) | Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi. | |
| CY1116260T1 (el) | Μεθοδοι παρασκευης παραγωγων κιναζολινονης | |
| MX2010009235A (es) | Estructuras fibrosas. | |
| EA201200939A1 (ru) | Липиды, липидные композиции и способы их применения | |
| EA201190306A1 (ru) | Улучшенная липидная композиция | |
| WO2013022922A3 (en) | Fibrous structures | |
| TW200630350A (en) | Dibenzyl amine compounds and derivatives | |
| EA201500650A1 (ru) | Фенилацетат l-орнитина и способы его получения | |
| RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
| TW200736235A (en) | Dibenzyl amine compounds and derivatives | |
| BRPI0603072A (pt) | materiais e métodos para produção eficiente de ácido lático | |
| BR112015015609A2 (pt) | preparação de ésteres de poli alfa-1,3-glucano e seus filmes | |
| EA200602273A1 (ru) | Замещённые гетероарильные и фенилсульфамоильные соединения | |
| EA201070187A1 (ru) | Модифицированные ферменты лецитин-холестерин ацилтрансферазы | |
| EA201070477A1 (ru) | Транс-кломифен для лечения метаболического синдрома | |
| EA201390659A1 (ru) | Способы лечения с применением липидных соединений | |
| ATE527270T1 (de) | Herstellung von organosilanestern | |
| MX344066B (es) | Estructuras fibrosas. | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| BR112015009748A2 (pt) | formulação de hdl reconstituída | |
| EA201070779A1 (ru) | Триазолсодержащие производные оксадиазола | |
| MX2013002145A (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. | |
| BR112015012968A2 (pt) | composições e métodos de uso | |
| WO2011066511A8 (en) | Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof |